Intelligence Feed event · Equity · 2026-10-13

    Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecast

    Question

    Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecast

    Direct answer

    Abbott Laboratories showed relative strength during the prior session, rising 2.23% to $101.82. Consensus earnings benchmarks set EPS expectations at $1.42, a 9.23% advance over the prior-year quarter, supported by projected top-line growth of 13.52% to $12.91 billion. The report on October 21 will offer an operational read on medical device and diagnostic demand across diversified healthcare portfolios.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-13
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecast”, revision 1, evidence through 2026-10-13. https://marketontology.com/market-events/2026-10-13/abbott-laboratories-approaches-q3-earnings-with-13-5-revenue-growth-forecast-3e1035

    EQUITY
    Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecast
    Abbott Laboratories showed relative strength during the prior session, rising 2.23% to $101.82. Consensus earnings benchmarks set EPS expectations at $1.42, a 9.23% advance over the prior-year quarter, supported by projected top-line growth of 13.52% to $12.91 billion. The report on October 21 will offer an operational read on medical device and diagnostic demand across diversified healthcare portfolios.
    ABT
    Impact
    64
    OCT 13
    SIG
    88%
    ABT
    Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecast
    Abbott Laboratories showed relative strength during the prior session, rising 2.23% to $101.82. Consensus earnings benchmarks set EPS expectations at $1.42, a 9.23% advance over the prior-year quarter, supported by projected top-line growth of 13.52% to $12.91 billion. The report on October 21 will offer an operational read on medical device and diagnostic demand across diversified healthcare portfolios.
    → Anticipated mid-teens revenue growth of 13.52% supports multiple stability for large-cap healthcare as ABT approaches its October 21 print.
    Impact
    Abbott Laboratories showed relative strength during the prior session, rising 2.23% to $101.82. Consensus earnings benchmarks set EPS expectations at $1.42, a 9.23% advance over the prior-year quarter, supported by projected top-line growth of 13.52% to $12.91 billion. The report on October 21 will offer an operational read on medical device and diagnostic demand across diversified healthcare portfolios.
    Affected
    ABT
    Transmission
    Anticipated mid-teens revenue growth of 13.52% supports multiple stability for large-cap healthcare as ABT approaches its October 21 print.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ABToperating earnings and revenue expansion into Q3 resultsUp1-4wProjected EPS of $1.42 (+9.23% YoY) and revenue of $12.91B (+13.52% YoY) scheduled for Oct 21.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month